Crohn's Disease patients benefit from Infliximab plus Azathioprine

According to a new study from the Mayo Clinic the use of infliximab (IFX) plus azathioprine (AZA) and infliximab monotherapy increase the likelihood of patients achieving long-term steroid-free clinical remission in patients with moderate to severe Crohn's disease. This study represents the first time longer term outcome data has been available to show the advantages of the combination therapy and IFX monotherapy.

Crohn's disease causes inflammation of the lining and wall of the large and/or small intestine. When inflamed, the lining of the intestinal wall is red and swollen, becomes ulcerated, and bleeds.

Results of this study will provide practitioners and their patients with more clinical data on how to use these drugs most appropriately to most effectively treat Crohns disease, said William J. Sandborn, MD, AGAF, professor of medicine and vice chair of the Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester.

An abbreviation for atrial fibrillation Full medical glossary
The body’s response to injury. Full medical glossary
relating to the intestines, the digestive tract between the stomach and the anus Full medical glossary
The section of gut, or gastrointestinal tract, from the stomach to the anus. Full medical glossary
The lessening or disappearance of the symptoms or signs of a disease. Full medical glossary
Any abnormal break in the epithelium, the outer layer of cells covering the open surfaces of the body. Full medical glossary